By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
Adding aliskiren to losartan in patients with nondiabetic chronic kidney disease does not result in a greater renal protection and increases their risk of hyperkalemia, a study found.
In a study, use of “high” dialysate calcium of 3.5 mEq/L in new hemodialysis patients was associated with poor outcomes.
People with breathing and heart problems, children, and the elderly may be particularly sensitive to fine particulate matter in the air.
The proportion of hemodialysis patients with congestive heart failure was 21% for those living below 1000 feet vs 19% and 13% for those living at 1000 to 4000 feet and above 4000 feet, respectively, a study found.
In the hemodialysis population, women have a 48% decreased risk of death compared with men in adjusted analyses, a study found.
Patients with low BMI had higher mortality risk even at higher spKt/V compared with patients with normal BMI and target range spKt/V of 1.2 to less than 1.4.
In a study of new dialysis patients, low proteinuria was associated with nearly triple the risk for early mortality compared with relatively normal proteinuria.
Patients with CKD who discontinued ACE inhibitors or angiotensin receptor blockers after a hyperkalemia episode had a 2.6-fold increased risk of all-cause mortality compared with patients who continued taking the drugs.
Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa.
In a study, approximately one-fifth of CKD patients with metabolic acidosis received a diagnostic code for it.
Hyperkalemia in patients with chronic kidney disease (CKD) stage 3 or 4 more than doubles their risk of progressing to CKD stage 5, a study found.
Gout that develops in kidney transplant recipients increases their risk of worse outcomes, according to 2 new studies.
In a study, two-thirds of hemodialysis patients met criteria for frailty, which impairs independence, cognition, mood, and quality of life.
Kidney disease patients who took magnesium-containing antacids were 15% more likely to experience hip fracture than nonusers of antacids.